Ypsomed Holding AG | Balance Sheet

Fiscal year is April-March. All values CHF Thousands.
2014
2015
2016
2017
2018
2019
Cash & Short Term Investments
16,164.00
16,243.00
25,507.00
38,884.00
32,111.00
12,083
Total Accounts Receivable
35,417.00
45,436.00
52,796.00
63,728.00
98,637.00
89,848
Inventories
52,261.00
51,791.00
56,139.00
55,900.00
66,810.00
54,203
Other Current Assets
10,742.00
10,028.00
13,921.00
16,866.00
20,753.00
22,655
Total Current Assets
114,584.00
123,498.00
148,363.00
175,378.00
218,311.00
178,789
Net Property, Plant & Equipment
160,437.00
150,946.00
153,752.00
158,615.00
192,314.00
268,644
Total Investments and Advances
9,376.00
8,591.00
8,151.00
10,378.00
10,195.00
8,723
Intangible Assets
61,296.00
69,007.00
72,978.00
73,575.00
77,139.00
81,419
Total Assets
354,528.00
361,211.00
388,871.00
421,801.00
500,239.00
587,748
ST Debt & Current Portion LT Debt
62,500.00
56,000.00
39,000.00
27,000.00
49,000.00
Accounts Payable
15,928.00
15,484.00
19,968.00
21,956.00
31,916.00
Income Tax Payable
1,076.00
1,854.00
2,966.00
4,036.00
6,819.00
Other Current Liabilities
23,533.00
27,290.00
43,391.00
50,014.00
54,718.00
Total Current Liabilities
103,037.00
100,628.00
105,325.00
103,006.00
142,453.00
Long-Term Debt
20,000.00
15,000.00
10,000.00
10,000.00
10,000.00
Provision for Risks & Charges
1,173.00
2,710.00
2,804.00
2,970.00
3,315.00
Deferred Taxes
7,766.00
7,403.00
2,735.00
117.00
617.00
Other Liabilities
1,087.00
470.00
14.00
57.00
32.00
Total Liabilities
126,366.00
120,574.00
121,035.00
120,005.00
158,697.00
Common Equity (Total)
228,162.00
240,637.00
267,836.00
301,796.00
341,542.00
Total Shareholders' Equity
228,162.00
240,637.00
267,836.00
301,796.00
341,542.00
Total Equity
228,162.00
240,637.00
267,836.00
301,796.00
341,542.00
Liabilities & Shareholders' Equity
354,528.00
361,211.00
388,871.00
421,801.00
500,239.00

About Ypsomed Holding

View Profile
Address
Brunnmattstrasse 6
Burgdorf Bern (Berne) 3401
Switzerland
Employees -
Website http://www.ypsomed.com
Updated 07/08/2019
Ypsomed Holding AG engages in the development and manufacture of injection systems for self-medication of drugs by patients, most notably used to treat diabetes. Its products include DiaExpert, BGMS, OmniPod, YpsoPump & Orbit, Pen needles, Injection systems, and Contract manufacturing. The company operates through the following business segments: Ypsomed Diabetes Care, Ypsomed Delivery Systems.